SCHEMBL26675397

SCHEMBL26675397

COc1ccccc1C(=O)n1nc(N)c2ccc(N3CCC3)nc21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 3/20 0.47
▸ ALOX15 P16050 2/20 0.47
▸ HTT P42858 4/20 0.47
▸ ALDH1A1 P00352 2/20 0.45
▸ KDM4E B2RXH2 1/20 0.45
▸ CYP2C9 P11712 1/20 0.45
▸ CYP2C19 P33261 1/20 0.45
▸ MAPT P10636 6/20 0.45
▸ SMN1; SMN2 Q16637 4/20 0.45
▸ TP53 P04637 2/20 0.45
▸ PKM P14618 1/20 0.45
▸ POLB P06746 4/20 0.44
▸ F2 P00734 3/20 0.44
▸ F12 P00748 2/20 0.43
▸ TTR P02766 1/20 0.42
▸ MGAM O43451 1/20 0.41
▸ AMY1A P0DUB6 1/20 0.41
▸ GAA P10253 1/20 0.41
▸ MIF P14174 1/20 0.41
▸ SI P14410 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29767955 1.00 HSD17B10 (0.47) HSD17B10ALOX15HTTALDH1A1KDM4E
SCHEMBL29767967 0.98 HSD17B10 (0.47) HSD17B10ALOX15HTTALDH1A1KDM4E
SCHEMBL26675414 0.98 HSD17B10 (0.47) HSD17B10ALOX15HTTALDH1A1KDM4E
SCHEMBL26675406 0.87 HSD17B10 (0.45) HSD17B10ALOX15HTTALDH1A1KDM4E
SCHEMBL29767954 0.87 HSD17B10 (0.45) HSD17B10ALOX15HTTALDH1A1KDM4E
SCHEMBL26675314 0.84 ALOX15 (0.49) HSD17B10ALOX15HTTALDH1A1KDM4E
SCHEMBL26675388 0.84 GBA1 (0.49) HTTALDH1A1MAPTSMN1; SMN2TP53
SCHEMBL29767951 0.84 GBA1 (0.49) HTTALDH1A1MAPTSMN1; SMN2TP53
SCHEMBL29767973 0.82 SMN1; SMN2 (0.52) HSD17B10HTTALDH1A1KDM4EMAPT
SCHEMBL26675390 0.82 SMN1; SMN2 (0.52) HSD17B10HTTALDH1A1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630549-B2 Pyrazoleamide derivatives HOFFMANN-LA ROCHE INC. (US) 2026-05-19 — — US claimed
US-20230382911-A1 PYRAZOLEAMIDE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2023-11-30 — — US claimed
US-12630549-B2 Pyrazoleamide derivatives HOFFMANN-LA ROCHE INC. (US) 2026-05-19 — — US disclosed
US-20230382911-A1 PYRAZOLEAMIDE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2023-11-30 — — US disclosed
US-20230382911-A1 PYRAZOLEAMIDE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2023-11-30 — — US disclosed
US-20230382911-A1 PYRAZOLEAMIDE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2023-11-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230382911-A1 PYRAZOLEAMIDE DERIVATIVES P2RY1, P2RX1, P2RX5 HSD17B10 2897/4885ALOX15 3863/4885HTT 4269/4885
US-12630549-B2 Pyrazoleamide derivatives CYP11B2, CYP11B1, ADRA1B HSD17B10 882/4885ALOX15 3315/4885HTT 3987/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback